 Alpine Immune Sciences Inc NASDAQ: ALPN announced the oral presentation of results from the dose-escalation portion of NEON-1 study of davoceticept monotherapy in advanced malignancies. The data were shared at the 2022 Annual Meeting of the American Association for Cancer Research. 